{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=1st+Line+NSCLC", "query": { "condition": "1st Line NSCLC" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 261, "total_pages": 27, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=1st+Line+NSCLC&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-27T00:03:21.481Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06422143", "title": "Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer", "NSCLC" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "sac-TMT", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 851, "start_date": "2024-06-10", "completion_date": "2031-02-12", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-06-27T00:03:21.481Z", "location_count": 20, "location_summary": "Little Rock, Arkansas • Burbank, California • San Diego, California + 15 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Burbank", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Golden", "state": "Colorado" }, { "city": "Grand Junction", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06422143" }, { "nct_id": "NCT05557591", "title": "A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "BNT116", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2023-04-21", "completion_date": "2028-05-16", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-06-27T00:03:21.481Z", "location_count": 9, "location_summary": "Los Angeles, California • Santa Monica, California • Louisville, Kentucky + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Farmington", "state": "New Mexico" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05557591" }, { "nct_id": "NCT00145418", "title": "Oxaliplatin and Docetaxel as First-line Therapy for Advanced Non-small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Oxaliplatin + Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncology Specialists, S.C.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2005-02", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2014-06-30", "last_synced_at": "2026-06-27T00:03:21.481Z", "location_count": 1, "location_summary": "Park Ridge, Illinois", "locations": [ { "city": "Park Ridge", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00145418" }, { "nct_id": "NCT02453282", "title": "Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small-Cell Lung Carcinoma NSCLC" ], "interventions": [ { "name": "MEDI4736 (Durvalumab)", "type": "BIOLOGICAL" }, { "name": "MEDI4736 (Durvalumab)+Tremelimumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel + Carboplatin", "type": "DRUG" }, { "name": "Gemcitabine + Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine + Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed + Cisplatin", "type": "DRUG" }, { "name": "Pemetrexed + Carboplatin", "type": "DRUG" }, { "name": "Tremelimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 1118, "start_date": "2015-07-21", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-06-27T00:03:21.481Z", "location_count": 35, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Yuma, Arizona + 28 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Yuma", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02453282" }, { "nct_id": "NCT00420732", "title": "Vaccine Maintenance Treatment for Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "HyperAcute-Lung Cancer Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "NewLink Genetics Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2007-01", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2020-05-28", "last_synced_at": "2026-06-27T00:03:21.481Z", "location_count": 2, "location_summary": "Chicago, Illinois • St Louis, Missouri", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00420732" }, { "nct_id": "NCT00147537", "title": "Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "CP-751,871", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "erlotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 282, "start_date": "2005-02", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2013-10-30", "last_synced_at": "2026-06-27T00:03:21.481Z", "location_count": 26, "location_summary": "Tucson, Arizona • Greenbrae, California • Los Angeles, California + 15 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00147537" }, { "nct_id": "NCT05098132", "title": "Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Non Small Cell Lung Cancer", "Untreated Advanced NSCLC", "1st Line NSCLC" ], "interventions": [ { "name": "STK-012", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "pemetrexed", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Synthekine", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 364, "start_date": "2022-01-25", "completion_date": "2029-01", "has_results": false, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-06-27T00:03:21.481Z", "location_count": 27, "location_summary": "Tucson, Arizona • Beverly Hills, California • Fullerton, California + 20 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05098132" }, { "nct_id": "NCT06463665", "title": "Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Non-squamous Non-small-cell Lung Cancer", "Advanced Squamous Non-Small Cell Lung Carcinoma", "Metastatic Non-squamous Non Small Cell Lung Cancer", "Metastatic Squamous Non-Small Cell Lung Carcinoma", "Non-small Cell Lung Cancer", "Non-small Cell Lung Cancer Stage III", "Non-small Cell Lung Cancer Stage IV", "Non-small Cell Lung Cancer Recurrent" ], "interventions": [ { "name": "Olvimulogene nanivacirepvec", "type": "BIOLOGICAL" }, { "name": "Platinum chemotherapy: carboplatin or cisplatin", "type": "DRUG" }, { "name": "Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC", "type": "DRUG" }, { "name": "Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Genelux Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 142, "start_date": "2024-09-26", "completion_date": "2029-07", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-06-27T00:03:21.481Z", "location_count": 15, "location_summary": "Bullhead City, Arizona • Clermont, Florida • Coral Springs, Florida + 11 more", "locations": [ { "city": "Bullhead City", "state": "Arizona" }, { "city": "Clermont", "state": "Florida" }, { "city": "Coral Springs", "state": "Florida" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Hialeah", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06463665" }, { "nct_id": "NCT03976323", "title": "Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Nonsquamous Non-small-cell Lung" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1003, "start_date": "2019-06-28", "completion_date": "2026-01-29", "has_results": true, "last_update_posted_date": "2026-02-25", "last_synced_at": "2026-06-27T00:03:21.481Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Muscle Shoals, Alabama • Burbank, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Burbank", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Orange City", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03976323" }, { "nct_id": "NCT02259582", "title": "A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nonsquamous Nonsmall Cell Neoplasm of Lung" ], "interventions": [ { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "demcizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OncoMed Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 82, "start_date": "2015-02", "completion_date": "2017-04-07", "has_results": true, "last_update_posted_date": "2020-09-09", "last_synced_at": "2026-06-27T00:03:21.481Z", "location_count": 18, "location_summary": "Rancho Mirage, California • San Francisco, California • New Haven, Connecticut + 14 more", "locations": [ { "city": "Rancho Mirage", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Ocala", "state": "Florida" }, { "city": "Skokie", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02259582" } ] }